Affix Labs Raises €1 Million for Distribution Expansion
Dutch green chemtech start-up Affix Labs has raised an investment of €1 million for the European expansion of its sustainable insect repellent.
The funding round, led by VP Capital and Oost NL, accelerates the roll-out of Affix-Labs' flagship product Repeltec and the company’s patented water-based solubility technology at a time when EU pesticide rules are tightening.
The company's surface insect repellent replaces the neurotoxic active ingredients responsible for growing insect resistance with a water-based, controlled-release alternative. The new capital will fund the European rollout.
The core innovation is a formulation method that dissolves oily, water-insoluble active ingredients into water-based systems. A controlled-release layer extends efficacy to 12 weeks. The flagship product, Repeltec, is dermatologically tested and contains no neurotoxic compounds.
With the new capital, Affix Labs--one of the winners of the 2020 CHEManager Innovation Pitch cohort--is expanding distribution in Germany, Austria, France, and Norway, with the UK and Poland to follow. Alongside its consumer product lines, the company is launching a white-label B2B model under the name "Powered by Affix Labs". FMCG companies, hospitality operators, and pest control manufacturers can use it to integrate the technology into their own product ranges.
“We have regulatory authorizations in four markets, a retail-ready product, and a regulatory environment moving in our direction. With this round we can stop proving the concept and start building distribution”, says Stijn de Roover, CEO, Affix Labs.
